Abstract
Anti-CD38 monoclonal antibody treatment is known to interfere with the blood compatibility test. Dithiothreitol (DTT) pre-treatment to denature surface CD38 on the reagent erythrocytes is a robust method to mitigate this interference and has been validated internationally (Transfusion, 2016;56;2964-2972). However, the distribution of common alloreactive antibodies differed widely between Asian and Caucasian population. Furthermore, in addition to anti-K, it remains unknown whether DTT pretreatment will decrease the sensitivity in the detection of other allogeneic antibodies common in Asia like anti-Miltenberger (anti-Mia).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
